<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974922</url>
  </required_header>
  <id_info>
    <org_study_id>091661</org_study_id>
    <secondary_id>20090713</secondary_id>
    <nct_id>NCT00974922</nct_id>
  </id_info>
  <brief_title>Vitamin D Deficiency in Patients With Hypertension</brief_title>
  <official_title>Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of Vitamin D replacement and the effects of an approved
      medication for hypertension, aliskiren (Tekturna), in patients with high blood pressure who
      have low levels of vitamin D in their blood. The study will compare the effects of vitamin D
      or aliskiren alone and in combination on 24-hour blood pressure and biochemical parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess whether aliskiren will lower clinic blood pressure and 24-hour blood
      pressure in patients with hypertension and vitamin D deficiency. Additionally, this study
      will further explore the potential additional effects of adding vitamin D to aliskiren in
      this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative/Sponsor Business Decision
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the baseline blood pressure measurement in 24-hour mean diastolic blood pressure.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline blood pressure measurement in 24-hour systolic BP, changes in awake and sleep systolic and diastolic BP, and changes from baseline in clinic systolic and diastolic BP.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two weeks of single-blind placebo, then randomized in a double-blind fashion to aliskiren 150 mg to 300 mg or Vitamin D3 (3000 I.U.) once daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren 150-300 mg orally once daily and Vitamin D3 3000 IU in combination once daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren (Tekturna)</intervention_name>
    <description>150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol (Vitamin D3)</intervention_name>
    <description>3,000 I.U. once daily for 6 weeks.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women over 21 years of age with a history of Stage 1 or 2 hypertension
             (defined as a seated diastolic BP â‰¥ 90 mmHg and &lt; 110 mmHg in the untreated state).

          -  Patients under treatment for hypertension must be willing and able to discontinue any
             previous antihypertensive medications for the duration of the study.

          -  25-hydroxyvitamin D levels &lt; 30 ng/ml and &gt; 12 ng/ml.

          -  Women of childbearing potential must be using a medically acceptable form of birth
             control for the duration of the trial, must have a negative serum pregnancy test at
             screening, and must have a negative urine pregnancy test within 7 days before
             initiating aliskiren therapy.

        Exclusion Criteria:

          -  Vitamin D levels &lt; 12 ng/ml

          -  Known hypersensitivity or allergy to aliskiren

          -  Clinic blood pressure &gt; 180/110 mmHg

          -  Known forms of secondary hypertension

          -  Chronic atrial fibrillation

          -  Uncontrolled or unstable cardiovascular diseases

          -  Shift or night workers

          -  Mid-arm circumference &gt; 42 cm in diameter

          -  Current or recent (&lt;1 year) alcohol or drug abuse

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William B White, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 23, 2012</lastchanged_date>
  <firstreceived_date>September 10, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut Health Center</investigator_affiliation>
    <investigator_full_name>William B. White</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
